Palo Alto, United States
Evommune, founded in 2020, is a pioneering company in the fields of Biotechnology, Health Care, and Life Sciences, based in the United States. The company is making strides in addressing the pervasive challenge of chronic inflammation, which affects millions globally and is a precursor to numerous serious health conditions.
Driven by its slogan, "Developing innovative therapies that target key drivers of chronic inflammatory diseases," Evommune is committed to advancing medical treatments that significantly enhance patients' quality of life by preventing the severe consequences of existing therapeutic limitations.
The company recently secured a substantial $7.50M in a Series B funding round on 28 June 2023, backed by Verition Fund Management. This investment underscores the confidence in Evommune's mission and its potential to deliver breakthroughs in inflammation management therapies.
Avalor Therapeutics